- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03700359
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
A Randomized, Open-label Study of Lobaplatin/Etoposide as First Line Therapy With or Without Anlotinib Maintenance Therapy in Patients With Extensive-stage Small-cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Small cell lung cancer (SCLC) accounts for about 20% of lung cancer, has a high degree of malignancy, short doubling time, early and widespread metastasis, is sensitive to chemotherapy and radiotherapy, and has a high initial response rate, but is prone to secondary drug resistance and relapse. The treatment is mainly based on systemic chemotherapy.
SCLC has a more abundant vascular network than NSCLC. Anti-tumor vascular therapy combined with chemotherapy is considered the most promising SCLC first-line anti-tumor strategy. Anlotinib Hydrochloride has an anti-angiogenic effect and inhibits tumor's growth. It has been reported that Anlotinib has the dual benefits of both overall survival and progression-free survival in the treatment of multiple tumors, and has initially demonstrated its safety and efficacy. The ALTER 0303 study results showed that Anlotinib benefited both the overall and progression-free survival of NSCLC patients. However, there is no clinical study to probe its relevance to small cell lung cancer, and few studies have examined the status of Anlotinib in first-line treatment.
This randomized, open-label, controlled study is to evaluate the efficacy and safety of sequential EL regimen with Anlotinib hydrochloride as first-line treatment for extensive-stage SCLC. The study plan to enroll 60 ES-SCLC subjects and will provide evidence for the use of Anlotinib for SCLC first-line treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jiexia Zhang, MD, PhD
- Phone Number: 86 20 83062830
- Email: drzjxcn@126.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- The First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Jiexia Zhang, prof.
- Phone Number: 13903056432
- Email: drzjxcn@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histopathologically confirmed patients with extensive small cell lung cancer;
- Karnofsky performance status ≥70;
- At least one lesion that can measured by CT;
- Expected to survive for at least 3 months;
Peripheral blood and liver and kidney function within the following allowable range (tested within 7 days before treatment);
- White blood cell (WBC) ≥3.0×109/L or Neutrophils (ANC) ≥1.5×109/L;
- Hemoglobin (HGB) ≥80 g/L;
- Platelet (PLT) ≥100×109/L;
- Liver transaminases(AST/ALT)<3.0 times the normal range limit;
- Total bilirubin(TBIL)<1.5 times the normal range limit;
- Creatinine(CREAT)<1.5 times the normal range limit;
- Patients of childbearing age (including female and male patients' partner) must take effective contraception methods;
- Signed informed consent;
- Known history of liver disease: Hepatitis B Virus (HBV) infection and Hepatitis B Virus DNA (HBV DNA ≥500 copies or ≥100 IU/ml); or Hepatitis C Virus (HCV) infection; or liver cirrhosis, etc.
- Human immunodeficiency virus (HIV);
- Subjects with difficulties in swallowing or known drug malabsorption; Those who meet each of the above criteria are included in the study.
Exclusion Criteria:
- Other pathological types of tumor except for small cell lung cancer;
- Patients with a history of severe allergies or allergies;
- Pregnancy or breastfeeding women;
- Patients who have previously participated in other clinical trials and have not yet terminated the trial;
- Combined with other tumors at the time of initial diagnosis;
- Patients who have previously participated in other clinical trials and have not yet terminated the trial;
- Patients who have acute infection that difficult to control;
- Drug abuse, substance abuse, chronic alcohol abuse, and AIDS patients. Those who meet any of the above criteria are not included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Anlotinib/Lobaplatin/Etoposide
EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
|
Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
Other Names:
Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Other Names:
Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Other Names:
|
ACTIVE_COMPARATOR: Lobaplatin/Etoposide
EL regimen for 4 cycles
|
Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Other Names:
Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival Time
Time Frame: Time from randomization to first documented progression, assessed for up to 2 years
|
Progression free survival (PFS) is defined as the time from date of randomization to the date of objective disease progression or death due to any cause.
Participants were censored at date of last PFS assessment prior to the cutoff date or the date of initiation of subsequent systemic anticancer therapy, whichever was earlier.
|
Time from randomization to first documented progression, assessed for up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)
Time Frame: Up to 2 years
|
Overall Response Rate (ORR) is the number of participants with a Complete Response (CR) and Partial Response (PR) divided by the total number of randomized participants per arm, then multiplied by 100.
Response is based on the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria.
Complete Response (CR) was defined as the disappearance of all target lesions.
Partial Response (PR) was defined as at least a 30% decrease in sum of longest diameter of target lesions compared to baseline or the complete disappearance of target lesions, with persistence of 1 or more nontarget lesion(s) and no new lesions.
|
Up to 2 years
|
Overall Survival
Time Frame: Time from randomization to death by any cause, assessed for up to 3 years
|
Overall survival (OS) is the duration from date of randomization to date of death from any cause.
Participants were censored at the date they were last known to be alive.
|
Time from randomization to death by any cause, assessed for up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing an Adverse Event (AE)
Time Frame: Up to 2 years
|
An AE is defined as any untoward medical occurrence in a participant administered study treatment which does not necessarily have to have a causal relationship with this treatment.
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure
|
Up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jiexia Zhang, The First Affiliated Hospital of Guangzhou Medical University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Etoposide
Other Study ID Numbers
- ES-SCLC 001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
Clinical Trials on Anlotinib Hydrochloride
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina
-
Peking University Third HospitalNot yet recruitingNon-Small Cell Lung Cancer